Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.

You may also be interested in...



Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.

Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.

MannKind Says Inhaled Insulin NDA On Track, Resumes Search For Partner

Afresa Phase III studies are complete, though FDA wants bioequivalence trial to support new inhaler device.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel